TrialAmerican journal of respiratory and critical care medicine2021

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One

Edith T Zemanick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.